Afluria Quadrivalent (influenza vaccine)
/ CSL Behring
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 13, 2022
CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI
(CSL Behring Press Release)
- "CSL Seqirus...announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in Belfast, United Kingdom. Data derived from a broad range of seasonal and pandemic influenza studies, including an oral presentation of influenza risk factors, will be shared....In addition, CSL Seqirus will host a symposium...on Monday, September 26, 2022, from 11:30-12:30 BST, highlighting the importance of influenza pandemic preparedness, the role of neuraminidase in influenza infection and the value of real-world evidence in public health decision making."
Clinical data • HEOR • Retrospective data • Infectious Disease • Influenza
September 26, 2022
New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates
(CSL Behring Press Release)
- "CSL Seqirus...announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more vulnerable populations such as children. The data are being presented in oral and poster sessions at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022."
Clinical data • Retrospective data • Infectious Disease • Influenza
1 to 2
Of
2
Go to page
1